Tien-Li Lee Acquires 6,000 Shares of Aardvark Therapeutics (NASDAQ:AARD) Stock

Aardvark Therapeutics, Inc. (NASDAQ:AARD) CEO Tien-Li Lee acquired 6,000 shares of the company’s stock in a transaction dated Thursday, September 11th. The shares were bought at an average cost of $7.82 per share, for a total transaction of $46,920.00. Following the completion of the acquisition, the chief executive officer directly owned 1,528,384 shares of the company’s stock, valued at approximately $11,951,962.88. The trade was a 0.39% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Tien-Li Lee also recently made the following trade(s):

• On Friday, September 12th, Tien-Li Lee bought 5,000 shares of Aardvark Therapeutics stock. The stock was purchased at an average price of $8.50 per share, with a total value of $42,500.00.
• On Wednesday, September 10th, Tien-Li Lee purchased 9,000 shares of Aardvark Therapeutics stock. The shares were purchased at an average cost of $7.91 per share, with a total value of $71,190.00.

Aardvark Therapeutics Price Performance

Shares of AARD stock opened at $8.59 on Friday. The stock’s 50-day simple moving average is $10.96 and its 200-day simple moving average is $10.55. Aardvark Therapeutics, Inc. has a fifty-two week low of $4.88 and a fifty-two week high of $19.58.

Aardvark Therapeutics (NASDAQ:AARD) last released its earnings results on Wednesday, August 13th. The company reported ($0.66) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.14).

Analysts Set New Price Targets

Several analysts have recently commented on AARD shares. Wall Street Zen downgraded shares of Aardvark Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 14th. Royal Bank Of Canada reduced their price objective on Aardvark Therapeutics from $20.00 to $19.00 and set an “outperform” rating for the company in a research note on Thursday, August 14th. Bank of America lowered their target price on Aardvark Therapeutics from $26.00 to $25.00 and set a “buy” rating on the stock in a research note on Thursday, August 28th. Finally, HC Wainwright assumed coverage on Aardvark Therapeutics in a research report on Monday, June 30th. They set a “buy” rating and a $40.00 price target for the company. Five analysts have rated the stock with a Buy rating, According to MarketBeat, Aardvark Therapeutics currently has an average rating of “Buy” and an average price target of $32.60.

Institutional Investors Weigh In On Aardvark Therapeutics

A number of institutional investors have recently added to or reduced their stakes in AARD. Decheng Capital LLC acquired a new position in Aardvark Therapeutics during the first quarter worth $29,419,000. Walleye Capital LLC acquired a new stake in shares of Aardvark Therapeutics in the first quarter valued at about $88,000. Braidwell LP purchased a new stake in shares of Aardvark Therapeutics during the first quarter worth about $3,755,000. Adage Capital Partners GP L.L.C. purchased a new stake in shares of Aardvark Therapeutics during the first quarter worth about $1,878,000. Finally, Cormorant Asset Management LP acquired a new position in shares of Aardvark Therapeutics during the 1st quarter worth about $6,009,000.

Aardvark Therapeutics Company Profile

Aardvark Therapeutics, Inc operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.